JPMorgan lowered the firm’s price target on QuidelOrtho (QDEL) to $11 from $15 and keeps an Underweight rating on the shares post the Q1 report. The firm cites weak respiratory results and China policy headwinds for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL: